PREFACE

The present issue marks the beginning of the seventeenth year of *Anti-Cancer Agents in Medicinal Chemistry*. The journal has received its last impact factor of 2.722. Due to the increasing number of exciting proposals, 14 issues will be published in 2017 instead of 12.

In the first issue of Volume 17, several review and research articles dealt with the activity of new heterocycles as potential anti-cancer drugs (Dalzoppo et al., Racané et al., Bhanushali et al., El-Gamal et al., Kaur Gill et al., Nguyen et al.). Apoptotic pathways and apoptotic inducers were reported with Ruthenium (II) complexes (Zheng et al.), cordycep (Zhou et al.), glycodendrimer PPI (Franiak-Pietryga et al.), PUFAs (Dolatkhah et al.), benzophenoxazines (Pal et al.).

A ruthenium-cycopentadienyl complex was studied *in vivo* in a breast cancer model by Mendes and collaborators.

A review proposed by Lu et al. reported updated knowledge on anti-cancer drug combinations.

O. Eloy and colleagues described a novel strategy to enhance cytotoxicity to HER2-positive breast cancer cells, whereas Gorin and collaborators discussed a new pathway to kill glioma (Stem like) cells.

I hope *Anti-Cancer Agents in Medicinal Chemistry* will continue throughout 2017 to provide scientists working in cancer research with new avenues and updated knowledge.

I would like to thank all the reviewers and the staff of the Editorial Office of Bentham Science and especially Noushaba Azher for her kind and professional assistance.

I wish an excellent and fruitful 2017 to all of you.

*Michelle Prudhomme*

*(Editor-in-Chief)*

Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France